Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware.[1][2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004.[1] In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.[3]
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.[4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO.[5] Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012.[6]
As of 2016[update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System,[7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".[1] The drug was rejected for FDA approval in 2017 and 2020.[8]
In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors.[3] In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650.[11] In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch.[12] In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.[13]
Notesedit
^ abc"Company Overview of Intarcia Therapeutics, Inc.", Bloomberg Businessweek, archived from the original on January 18, 2013, retrieved November 15, 2012
^ ab"Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy". www.fiercebiotech.com. April 2014.
^"INTARCIA THERAPEUTICS, INC.", AMENDMENT NO. 1 TO FORM S-1, SEC, March 18, 2005, retrieved November 15, 2012
^Ron Leuty (November 15, 2012), "Intarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area", San Francisco Business Times, retrieved November 15, 2012
^"Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus", ClinicalTrials.gov, May 1, 2012, retrieved November 15, 2012
^"Intarcia's diabetes drug implant ITCA 650 receives second FDA rejection". 27 March 2020.
^"AtTaIntarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area". BizJournals. November 15, 2012. Retrieved November 7, 2013.
^"Direct Investments". Greenspring Associates. November 7, 2013. Retrieved November 7, 2013.
^Winslow, Ron (April 28, 2015). "Startup Intarcia Raises $225 Million". Wall Street Journal – via www.wsj.com.
^"Intarcia raises $75M, touts final data as it preps to launch once-yearly diabetes drug implant". www.fiercebiotech.com. 9 May 2016.
^"Diabetes 'Unicorn' Raises Final VC Round Before IPO". Fortune.
intarcia, therapeutics, american, biopharmaceutical, company, based, boston, incorporated, under, laws, delaware, founded, 1995, under, name, biomedicines, changed, present, name, 2004, 2013, intarcia, relocated, headquarters, boston, keeping, manufacturing, f. Intarcia Therapeutics is an American biopharmaceutical company based in Boston MA and incorporated under the laws of Delaware 1 2 It was founded in 1995 under the name BioMedicines and changed to its present name in 2004 1 In 2013 Intarcia relocated its headquarters to Boston keeping its manufacturing facility in Hayward CA In addition to Boston and Hayward Intarcia also has a location in Research Triangle Park North Carolina where it discovers and develops peptides for its drug delivery system 3 Intarcia Therapeutics Inc Company typePrivateIndustrypharmaceutical industryFoundedHayward California United States 1995 1995 HeadquartersBoston MA United StatesKey peopleKurt C Graves Chairman President and CEO ProductsMedici Drug Delivery SystemWebsiteintarcia wbr com In 2005 the executive leadership of Intarcia was largely vested in two people Karling Leung and James Ahlers President CEO Director and Vice President CFO Finance amp Operations Officer respectively 4 By 2012 Kurt Graves had replaced Karling Leung as President and CEO 5 Kurt Graves has been with Intarcia since August 2010 first serving as Executive Chairman before becoming President and CEO in April 2012 6 As of 2016 update Intarcia is engaged in development of a potential once a year type 2 diabetes treatment Referred to as ITCA 650 the therapeutic consists of exenatide delivered via its Medici Drug Delivery System 7 a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides 1 The drug was rejected for FDA approval in 2017 and 2020 8 Investors editIn November 2012 Intarcia received 210M in preferred stock and debt financing from The Baupost Group Farallon Capital Management New Enterprise Associates New Leaf Venture Partners and Venrock Associates 9 Other Investors include Greenspring Associates 10 Alta Partners and Granite Venture Partners In April 2014 Intarcia secured an additional 200M in financing RA Capital led the round and was joined by new and existing investors 3 In April 2015 the company raised 225M in exchange for 1 5 of future global net sales of ITCA 650 11 In May 2016 Intarcia secured an additional 75M in financing to scale up manufacturing and inventory in anticipation of ITCA 650s global launch 12 In September 2016 Intarcia raised an additional 215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs 13 Notes edit a b c Company Overview of Intarcia Therapeutics Inc Bloomberg Businessweek archived from the original on January 18 2013 retrieved November 15 2012 Exhibit 4 1 SEC retrieved November 15 2012 a b Investors pump 200M into Intarcia s PhIII for once yearly diabetes therapy www fiercebiotech com April 2014 INTARCIA THERAPEUTICS INC AMENDMENT NO 1 TO FORM S 1 SEC March 18 2005 retrieved November 15 2012 Ron Leuty November 15 2012 Intarcia raises 210M as it pushes once a year diabetes treatment into Phase III moves HQ to Boston area San Francisco Business Times retrieved November 15 2012 Stocks Bloomberg com Study of ITCA 650 Exenatide in DUROS in Subjects With Type 2 Diabetes Mellitus ClinicalTrials gov May 1 2012 retrieved November 15 2012 Intarcia s diabetes drug implant ITCA 650 receives second FDA rejection 27 March 2020 AtTaIntarcia raises 210M as it pushes once a year diabetes treatment into Phase III moves HQ to Boston area BizJournals November 15 2012 Retrieved November 7 2013 Direct Investments Greenspring Associates November 7 2013 Retrieved November 7 2013 Winslow Ron April 28 2015 Startup Intarcia Raises 225 Million Wall Street Journal via www wsj com Intarcia raises 75M touts final data as it preps to launch once yearly diabetes drug implant www fiercebiotech com 9 May 2016 Diabetes Unicorn Raises Final VC Round Before IPO Fortune External links editOfficial website nbsp This article about a medical pharmaceutical or biotechnological corporation or company is a stub You can help Wikipedia by expanding it vte nbsp This United States corporation or company article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Intarcia Therapeutics amp oldid 1155787441, wikipedia, wiki, book, books, library,
